fashion -WSS

fashion

author：explore 2025-08-11 11:45:42 - browse：75

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： 5 important ways Henrietta Lacks changed medical science

explore

WSS

Wildfire pollution widens asthma inequities on Long Island

Private equity could exacerbate cardiology's overuse problem, experts fear

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

New weight loss drugs vying to be the next Wegovy or Mounjaro

EQRx, failed developer of low

Sage hopes for a blockbuster in antidepressant now before FDA

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

ChatGPT in medicine: STAT answers readers' burning questions

EQRx, failed developer of low

Alkermes shareholders re

NIH launches clinical trials and new research office for long Covid

Hollywood unions extend contract negotiations for actors

EQRx, failed developer of low

Duchenne breakthrough therapy leaves behind pioneering families

Food makers to regulators: Ultra

Medical records are filled with copy

Wildfire pollution widens asthma inequities on Long Island

explore

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Vertex non

Generate Biomedicines machine learning biotech raises $273M

What to make of Biden’s latest efforts on cancer research

IRA could hurt research into orphan drugs for rare diseases

Scientists inch closer to single

focus

knowledge

leisure time

explore